Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 2:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 1,199 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: RAYOS Clear all
Completed Phase 2 Interventional Results available

Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate

NCT02268175
View directory record Official record
Conditions
Prostate Adenocarcinoma, Prostate Cancer, High Risk Prostate Cancer
Interventions
Enzalutamide, Abiraterone Acetate, Prednisone, Leuprolide Acetate
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
4
States / cities
Baltimore, Maryland • Boston, Massachusetts • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Oct 25, 2026, 2:29 PM EDT
Completed Phase 2 Interventional

A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

NCT02723994
View directory record Official record
Conditions
Leukemia
Interventions
Ruxolitinib, Asparaginase Erwinia Chrysanthemi, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Thioguanine, Vincristine Sulfate
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
1 Year to 21 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
103
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 87 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 25, 2026, 2:29 PM EDT
Recruiting Phase 2 Interventional

Mycophenolate Mofetil w/ Prednisone for Immune Related Hepatitis From Checkpoint Inhibitor Therapy

NCT07663422
View directory record Official record
Conditions
Immune-mediated Hepatitis, Immune-related Adverse Event
Interventions
Mycophenolate Mofetil plus prednisone
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 25, 2026, 2:29 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)

NCT04497844
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Niraparib+ Abiraterone acetate fixed dose combination (FDC), Abiraterone acetate (AA), Prednisone, Placebo FDC, Placebo AA
Combination Product · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
696 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
53
States / cities
Homewood, Alabama • Phoenix, Arizona • Tucson, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 25, 2026, 2:29 PM EDT
Active, not recruiting Phase 3 Interventional

Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients

NCT04824092
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma
Interventions
Tafasitamab, Lenalidomide, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Tafasitamab placebo, Lenalidomide placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
899 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
47
States / cities
Daphne, Alabama • Anaheim, California • Clovis, California + 44 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 25, 2026, 2:29 PM EDT
Terminated Phase 2 Interventional Results available

Docetaxel, Radiation Therapy, and Prednisone in Treating Patients Who Have Undergone Surgery For Prostate Cancer

NCT00348816
View directory record Official record
Conditions
Prostate Cancer
Interventions
docetaxel, prednisone, Radical prostatectomy, Radiation therapy
Drug · Procedure · Radiation
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2017 · Synced Oct 25, 2026, 2:29 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer

NCT00411528
View directory record Official record
Conditions
Metastatic Hormone Refractory Prostate Cancer
Interventions
Patupilone, prednisone, docetaxel
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
11
States / cities
La Jolla, California • Aurora, Colorado • Norwalk, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 25, 2026, 2:29 PM EDT
Completed Phase 3 Interventional Results available

Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer

NCT00744497
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Placebo, Dasatinib, Docetaxel, Prednisone
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,930 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
43
States / cities
Mobile, Alabama • Anchorage, Alaska • Fayetteville, Arkansas + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Oct 25, 2026, 2:29 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer

NCT04709276
View directory record Official record
Conditions
Metastatic Prostate Neuroendocrine Carcinoma, Metastatic Prostate Cancer
Interventions
Nivolumab, Ipilimumab, Carboplatin, Cabazitaxel
Drug
Lead sponsor
Andrew J. Armstrong, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
3
States / cities
New York, New York • Durham, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 25, 2026, 2:29 PM EDT
Recruiting Phase 3 Interventional

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

NCT03678025
View directory record Official record
Conditions
Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Abiraterone, Bicalutamide, Degarelix, Docetaxel, Flutamide, Goserelin Acetate, Histrelin Acetate, Leuprolide Acetate, Nilutamide, Orchiectomy, Prednisone, Quality-of-Life Assessment, Radiation Therapy, Radical Prostatectomy, Triptorelin
Drug · Procedure · Other + 1 more
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older · Male only
Enrollment
1,273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2036
U.S. locations
334
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 253 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 25, 2026, 2:29 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy, Bone Marrow Transplantation, and Radiation Therapy in Treating Infants With Acute Lymphoblastic Leukemia

NCT00002785
View directory record Official record
Conditions
Leukemia
Interventions
filgrastim, asparaginase, cyclophosphamide, cyclosporine, cytarabine, daunorubicin hydrochloride, dexamethasone, etoposide, leucovorin calcium, mercaptopurine, mesna, methotrexate, methylprednisolone, pegaspargase, prednisone, therapeutic hydrocortisone, vincristine sulfate, allogeneic bone marrow transplantation, low-LET cobalt-60 gamma ray therapy, low-LET photon therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 1 Year
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2007
U.S. locations
30
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Oct 25, 2026, 2:29 PM EDT
Withdrawn Not applicable Interventional

P-Co-Li (Pulmonary Covid-19 Study)

NCT04782700
View directory record Official record
Conditions
Covid19, Lung Inflammation, Hypoxemic Respiratory Failure
Interventions
Steroid Taper (Prednisone)
Other
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Feb 16, 2022 · Synced Oct 25, 2026, 2:29 PM EDT
Not yet recruiting Phase 1 Interventional

Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients

NCT07714421
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma, Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
Biospecimen Collection, Computed Tomography, Cyclophosphamide, Doxorubicin, Epcoritamab, Magnetic Resonance Imaging, Polatuzumab Vedotin, Positron Emission Tomography, Prednisone, Rituximab
Procedure · Drug · Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
70 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 25, 2026, 2:29 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVE

NCT03312907
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Belimumab, Rituximab, Rituximab-placebo, Standard therapy (Including Immunosuppressants), Standard therapy (Excluding Immunosuppressants), Steroid Taper
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
28
States / cities
Birmingham, Alabama • La Mesa, California • San Leandro, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Oct 25, 2026, 2:29 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma

NCT01818752
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Carfilzomib, Bortezomib, Melphalan, Prednisone
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
955 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
14
States / cities
Fresno, California • Greenbrae, California • Modesto, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2019 · Synced Oct 25, 2026, 2:29 PM EDT
Terminated Phase 4 Interventional Results available

Prednisone Withdrawal Versus Prednisone Maintenance After Kidney Transplant

NCT00596947
View directory record Official record
Conditions
Transplants and Implants
Interventions
Prednisone, rabbit antithymocyte globulin, Tacrolimus, Mycophenolate mofetil
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
19 Years to 74 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 25, 2026, 2:29 PM EDT
Active, not recruiting Phase 1 Interventional

Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies

NCT05270057
View directory record Official record
Conditions
B-cell Lymphoma, Burkitt Lymphoma
Interventions
Etoposide, Doxorubicin, Cyclophosphamide, Rituximab, Vincristine, Prednisone, Loncastuximab Tesirine 0.075 mg/kg by IV, Loncastuximab tesirine 0.12 mg/kg by IV, Loncastuximab tesirine 0.15 mg/kg by IV
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Dallas, Texas • Madison, Wisconsin • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 25, 2026, 2:29 PM EDT
Completed Phase 1 Interventional Results available

Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)

NCT03792256
View directory record Official record
Conditions
Leukemia, Lymphocytic, Lymphoblastic Lymphoma, T-cell Lymphoma, T-cell Leukemia, Recurrent Disease, Acute Leukemia
Interventions
Palbociclib, Cytarabine, Methotrexate, Hydrocortisone, Doxorubicin, Prednisolone, Vincristine, Pegaspargase, Prednisone
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
12 Months to 31 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
19
States / cities
Birmingham, Alabama • Loma Linda, California • Orange, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Oct 25, 2026, 2:29 PM EDT
Completed Not applicable Interventional Results available

A Phase 2 Trial of Rituximab and Corticosteroid Therapy for Newly Diagnosed Chronic Graft Versus Host Disease

NCT00350545
View directory record Official record
Conditions
Graft vs Host Disease
Interventions
Rituximab, Prednisone, Cyclosporine A, tacrolimus
Drug
Lead sponsor
Stanford University
Other
Eligibility
1 Year to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Oct 25, 2026, 2:29 PM EDT
Active, not recruiting Phase 1 Interventional

Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

NCT04884035
View directory record Official record
Conditions
Lymphoma, B-Cell
Interventions
CC-220, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, CC-99282, Polatuzumab vedotin
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
15
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Duarte, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 25, 2026, 2:29 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma

NCT00715208
View directory record Official record
Conditions
Relapsed Follicular Lymphoma
Interventions
rituximab, cyclophosphamide, doxorubicin, VELCADE, prednisone
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
42
States / cities
Muscle Shoals, Alabama • Burbank, California • Fountain Valley, California + 38 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2013 · Synced Oct 25, 2026, 2:29 PM EDT
Completed Phase 4 Interventional Results available

Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients

NCT00866879
View directory record Official record
Conditions
Renal Transplant Rejection
Interventions
Sirolimus, Demographic Data, Medical History, and Donor Data, Blood Draws for Control Group, Blood Draws for Experimental Group, Donor Blood Draws, Donor Information, Kidney Biopsy
Drug · Other · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 70 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 28, 2019 · Synced Oct 25, 2026, 2:29 PM EDT
Completed Phase 2 Interventional Results available

Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis

NCT02097303
View directory record Official record
Conditions
Prostate Cancer
Interventions
Concurrent use of Radium Ra 223 dichloride and Abiraterone Acetate plus Prednisone
Drug
Lead sponsor
Carolina Research Professionals, LLC
Other
Eligibility
18 Years and older · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
5
States / cities
Towson, Maryland • Omaha, Nebraska • Syracuse, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2018 · Synced Oct 25, 2026, 2:29 PM EDT
Completed Phase 2 Interventional Results available

Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)

NCT00224874
View directory record Official record
Conditions
Graft vs Host Disease, Immune System Disorders
Interventions
Etanercept, Mycophenolate Mofetil, Denileukin Diftitox, Pentostatin
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
19
States / cities
Duarte, California • San Diego, California • Stanford, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 25, 2026, 2:29 PM EDT